

REMARKS/ARGUMENTS

Original claims 1-38 are herein canceled without prejudice. Claims 39-83 are newly presented. The Table at the top of p. 41 has been replaced by a new table.

Response to the Restriction Requirement

Applicants elect Group II without traverse and provide new claims in accord with the election.

Support for the Amendments to the Specification.

The substitute Table is identical to the table it replaces, except for the values entered for the compound of Example 47. Those values are supported by the specification at p.43 which gives the compound name of the compound of Example 47. In the previous version of the table, the first column entry had been dropped and the other column entries were shifted to the left accordingly. In view of the above, the Applicants believe the amendments to the specification add no new matter, and respectfully request their entry.

Support for the Amendments to the Claims.

New claims 39-83 are similar to those previously indicated to be allowable in the immediate parent. The compound subject matter of the claims finds support *inter alia* in the specification at pp. 40 and 41. In the table on p. 41, the compound of example 47 has its corresponding values shifted one column to the left such that the last column on the right is empty. The correct compound data is set forth for Example 47 at p. 43.

Support for the pharmaceutical composition claims and methods of treatment claims involving these compounds is found throughout the specification and in the previous versions of such claims.

In view of the above, the Applicants believe the amendments to the claims add no new matter and respectfully request their entry.

Comments Regarding the Notice of Allowance in the Parent Application

In the reasons for allowance in the parent application, the Examiner stated that DE362329A1 did not disclose a center benzene ring bearing a chlorine substituent. Applicants note for the record that this reference at p. 37 discloses two compounds (see top two figures) having a single chlorine substituent on the center benzene ring.

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 925-472-5000.

Respectfully submitted,



Frank J. Mycroft
Reg. No. 46,946

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 925-472-5000
Fax: 415-576-0300
Attachments
FJM:fjm
60228549 v1
60228549_1.DOC